StreetInsider.com News Articles

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Jun 30

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931092.html

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Jun 30

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931092.html

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Thu, 06 Aug 2026 11:58:00 -0400

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region

BETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the Company's DCVax®-L products and technology to Saudi Arabia. SPIMACO is one of the largest

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Thu, 06 Aug 2026 11:58:00 -0400

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Thu, 06 Aug 2026 11:58:00 -0400

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Thu, 06 Aug 2026 11:58:00 -0400

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 29

Fri, 31 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26851701.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 29

Fri, 31 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26851701.html

Form 424B5 NORTHWEST BIOTHERAPEUTIC

Fri, 31 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260731/26851688.html

Form 424B5 NORTHWEST BIOTHERAPEUTIC

Fri, 31 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260731/26851688.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 17

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786466.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 17

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786466.html

NWBio updated DCVax-L trial data suggests original survival gains were underestimated

Wed, 08 Jul 2026 14:25:09 -0400

Northwest Biotherapeutics (OTCQB: NWBO) presented updated survival data from its Phase III trial of DCVax-L for glioblastoma at the 2026 Annual Meeting of the British Neuro-Oncology Society, according to a company statement.

The new analyses, conducted by independent statisticians using individual patient-level data (IPD), suggest the survival benefit previously reported from the trial was likely underestimated. The original analysis, which relied on cohort-level data, found a median survival advantage of 2.8 months for DCVax-L patients.

Using two statistical methods — propensity score matching (PSM) and inverse probability weighting (IPW) — the independent statisticians compared DCVax-L patients against controls drawn from several randomized

NWBio updated DCVax-L trial data suggests original survival gains were underestimated

Wed, 08 Jul 2026 14:25:09 -0400

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

BETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax®-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

NWBio to present DCVax-L survival data at UK neuro-oncology meeting

Thu, 02 Jul 2026 14:19:20 -0400

Northwest Biotherapeutics (OTCQB: NWBO) announced that its Chief Technical Officer, Dr. Marnix Bosch, will present survival data on its DCVax-L therapy at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS) on July 3.

The presentation, titled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses," is scheduled for 10:00 a.m. GMT and will examine the association between DCVax-L treatment and patient survival using propensity score matching methodologies.

The company said the slide deck will be posted to its website following the presentation.

DCVax-L is Northwest Biotherapeutics' lead therapy candidate for glioblastoma, an aggressive form of primary brain cancer. The company has

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The presentation is scheduled for Friday, July 3, at 10:00 a.m. GMT, and will address the association between DCVax-L treatment and patient survival using propensity score matching methodologies (PSM). The

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Mar 31

Fri, 15 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26506799.html

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Mar 31

Fri, 15 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26506799.html